Immunic, Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 20 consecutive business days, resolving a prior listing deficiency.
Key takeaways
Immunic received Nasdaq notification on March 27, 2026, confirming compliance with minimum bid price requirement.
Compliance was achieved by maintaining closing bid price at $1.00+ per share for 20 consecutive business days from February 27 to March 26, 2026.
The matter is now closed, eliminating immediate delisting risk related to bid price deficiency.
Company announced compliance via press release on April 1, 2026, attached as Exhibit 99.1.
Immunic is a late-stage biotechnology company developing oral therapies for neurologic diseases, with lead program vidofludimus calcium in phase 3 trials for relapsing multiple sclerosis.